Grant: Discovery Grants Program - Individual
University of British Columbia
$46,000.00
Heterocycles in natural products: Enzymes, pathways, and chemistry
FY 2018-19
Summary
Molecules isolated from living organisms are some of the most chemically complex and medicinally relevant compounds ever isolated. These natural product molecules play critical roles as antibiotics and other drugs. My research group is interested in understanding how nature constructs natural products, and our long-term goal is to harness this knowledge to develop new molecules and to understand how novel enzymes function. In this program, we will use indolmycin, a unique antibiotic, with translational potential as an agent against methicillin-resistant Staphylococcus aureus (MRSA), as a starting point to elucidate fundamental bioorganic chemistry. Previous work in my group identified the indolmycin gene cluster and the roles of several unique enzymes in building this unique structure. These prior results set the stage to elucidate new enzyme mechanisms and investigate related systems identified from genomic mining. Furthermore, we are now positioned to develop new molecules by combining techniques from organic chemistry, enzymology, and genetic engineering.*In this program, we will pursue three related objectives: first, we will use X-ray crystallography to solve the structures of indolmycin biosynthetic enzymes. Several of the indolmycin enzymes catalyze reactions that are unprecedented, and we want to understand how they work. By generating molecular blueprints for these enzymes, we will understand the architecture of these proteins and set the stage for engineering them to do new reactions. Second, we will elucidate three new pathways related to indolmycin. Using bioinformatics tools, we have discovered three gene clusters that have genes related to the indolmycin genes. Our goals are to understand the enzymes encoded by these new gene clusters and to elucidate the products of these new pathways. Third, we will generate a library of indolmycin derivatives by combining techniques from chemistry and biology. This work will harness and engineer the indolmycin gene cluster to make molecules that we can test for their antibiotic activity. Overall, our work will provide fundamental insights into enzymology, biosynthesis, and bioorganic chemistry and provide sustainable access to library of new indolmycin-like molecules to enable downstream translational efforts to develop new antibiotics.*
Program
Discovery Grants Program - Individual
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
RGPIN-2016-03778
Name nom
Ryan, Katherine
Department département
Chemistry
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2016
Award amount
46000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1504
Committee name en
Chemistry
Committee name fr
Chimie
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3705
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Bio-organic chemistry
Research subject fr
Chimie bio-organique
Partie
3
Nb partie
5
Application title
Heterocycles in natural products: Enzymes, pathways, and chemistry
Keyword
NSERC
Application summary
Molecules isolated from living organisms are some of the most chemically complex and medicinally relevant compounds ever isolated. These natural product molecules play critical roles as antibiotics and other drugs. My research group is interested in understanding how nature constructs natural products, and our long-term goal is to harness this knowledge to develop new molecules and to understand how novel enzymes function. In this program, we will use indolmycin, a unique antibiotic, with translational potential as an agent against methicillin-resistant Staphylococcus aureus (MRSA), as a starting point to elucidate fundamental bioorganic chemistry. Previous work in my group identified the indolmycin gene cluster and the roles of several unique enzymes in building this unique structure. These prior results set the stage to elucidate new enzyme mechanisms and investigate related systems identified from genomic mining. Furthermore, we are now positioned to develop new molecules by combining techniques from organic chemistry, enzymology, and genetic engineering.*In this program, we will pursue three related objectives: first, we will use X-ray crystallography to solve the structures of indolmycin biosynthetic enzymes. Several of the indolmycin enzymes catalyze reactions that are unprecedented, and we want to understand how they work. By generating molecular blueprints for these enzymes, we will understand the architecture of these proteins and set the stage for engineering them to do new reactions. Second, we will elucidate three new pathways related to indolmycin. Using bioinformatics tools, we have discovered three gene clusters that have genes related to the indolmycin genes. Our goals are to understand the enzymes encoded by these new gene clusters and to elucidate the products of these new pathways. Third, we will generate a library of indolmycin derivatives by combining techniques from chemistry and biology. This work will harness and engineer the indolmycin gene cluster to make molecules that we can test for their antibiotic activity. Overall, our work will provide fundamental insights into enzymology, biosynthesis, and bioorganic chemistry and provide sustainable access to library of new indolmycin-like molecules to enable downstream translational efforts to develop new antibiotics.*